Inclusion Criteria:  Age ≥18 years. Patients with possible/probable/proven invasive fungal disease according to EORTC-MSG diagnostic criteria. Patients received ABCD alone or in combination with other antifungals on either empirical, diagnosis-driven or targeted therapy. There is no limit to the patient's previous treatment plan.  Exclusion Criteria:  Patients judged by clinicians to be unsuitable for this study. Patients with incomplete data or other factors affecting the judgment of efficacy and safety.